Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

1. Smoking Cessation in Cancer Patients

an effect in recent quitters show an improvement in recurrence rates in patients who quit after * Including neoplasms of the nasopharynx, larynx, trachea, bronchus, lung, pleura and intrathoracic organs their cancer diagnosis compared to those who continue to smoke. Among 321 patents with non-small cell lung cancer, recent quitters had half the relative risk of disease-free survival (= 0.5, 95% CI = 0.3-1.0, P = 0.052). 21 In 153 patients with laryngeal cancer, recurrence rates were 28.7% in patients (...) tobacco almost triples the risk of death among Australians. 1 About 21,000 deaths are attributed to smoking each year. 2 The main causes of death from smoking are from cancer (8,000 per year; 16 different cancer types, the majority due to lung cancer), heart disease and stroke (5,000 per year) and respiratory disease (4,000 per year). 3 Continuation of smoking after a cancer diagnosis (which itself significantly increases the risk of death with a five-year relative mortality of 30%) 4 has similar

2021 Clinical Oncology Society of Australia

2. Tucatinib (Tukysa) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer

Tucatinib (Tukysa) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer Tucatinib (Tukysa®) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer - Repository of AIHTA GmbH English | Browse - - - Tucatinib (Tukysa®) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer Grössmann, N. (2020): Tucatinib (Tukysa® (...) ) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer. Oncology Fact Sheet Nr. 37. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 74kB Item Type: Oncology Fact Sheet Subjects: > > > > Language: English Series Name: Oncology Fact Sheet Nr. 37 Deposited on: 04 Jan 2021 14:13 Last Modified: 04 Jan 2021 16:33 Repository Staff Only: © Copyright ,

2021 Austrian Institute of Health Technology Assessment

3. Selpercatinib (Retsevmo) for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer

Selpercatinib (Retsevmo) for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer Selpercatinib (Retsevmo®) for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer - Repository of AIHTA GmbH English | Browse - - - Selpercatinib (Retsevmo®) for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer (...) Grössmann, N. (2020): Selpercatinib (Retsevmo®) for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer. Oncology Fact Sheet Nr. 36. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 87kB Item Type: Oncology Fact Sheet Subjects: > > > > Language: English Series Name: Oncology Fact Sheet Nr. 36 Deposited on: 04 Jan 2021 14:13 Last Modified: 04 Jan 2021 16:33 Repository Staff Only: © Copyright ,

2021 Austrian Institute of Health Technology Assessment

4. Avelumab (Bavencio) as monotherapy for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma

Avelumab (Bavencio) as monotherapy for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma Avelumab (Bavencio®) as monotherapy for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma - Repository of AIHTA GmbH English | Browse - - - Avelumab (Bavencio®) as monotherapy for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma Grössmann, N (...) . (2020): Avelumab (Bavencio®) as monotherapy for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma. Oncology Fact Sheet Nr. 31. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 87kB Item Type: Oncology Fact Sheet Subjects: > > > > Language: English Series Name: Oncology Fact Sheet Nr. 31 Deposited on: 04 Jan 2021 14:11 Last Modified: 04 Jan 2021 16:34 Repository Staff Only: © Copyright ,

2021 Austrian Institute of Health Technology Assessment

5. Trastuzumab deruxtecan (Enhertu) in patients with previously treated HER2-positive breast cancer

Trastuzumab deruxtecan (Enhertu) in patients with previously treated HER2-positive breast cancer Trastuzumab deruxtecan (Enhertu®) in patients with previously treated HER2-positive breast cancer - Repository of AIHTA GmbH English | Browse - - - Trastuzumab deruxtecan (Enhertu®) in patients with previously treated HER2-positive breast cancer Grössmann, N. (2020): Trastuzumab deruxtecan (Enhertu®) in patients with previously treated HER2-positive breast cancer. Oncology Fact Sheet Nr. 32. Preview

2021 Austrian Institute of Health Technology Assessment

6. Pembrolizumab (Keytruda) as monotherapy for the first-line treatment of MSI H or dMMR colorectal cancer

Pembrolizumab (Keytruda) as monotherapy for the first-line treatment of MSI H or dMMR colorectal cancer Pembrolizumab (Keytruda®) as monotherapy for the first-line treatment of MSI H or dMMR colorectal cancer - Repository of AIHTA GmbH English | Browse - - - Pembrolizumab (Keytruda®) as monotherapy for the first-line treatment of MSI H or dMMR colorectal cancer Grössmann, N. (2020): Pembrolizumab (Keytruda®) as monotherapy for the first-line treatment of MSI H or dMMR colorectal cancer

2021 Austrian Institute of Health Technology Assessment

7. Malignant hyperthermia

,ChairofWorkingParty Summary Malignant hyperthermia is de?ned in the International Classi?cation of Diseases as a progressive life- threatening hyperthermic reaction occurring during general anaesthesia. Malignant hyperthermia has an underlying genetic basis, and genetically susceptible individuals are at risk of developing malignant hyperthermia if they are exposed to any of the potent inhalational anaesthetics or suxamethonium. It can also be described as a malignant hypermetabolic syndrome. There are no speci?c (...) Malignant hyperthermia Guidelines Malignant hyperthermia 2020 October 2020Guidelines Malignanthyperthermia2020 GuidelinefromtheAssociationofAnaesthetists P.M.Hopkins, 1 T.Girard, 2 S.Dalay, 3 B.Jenkins, 4 A.Thacker, 5 M.Patteril 6 andE.McGrady 7 1Consultant,MalignantHyperthermiaUnit,StJames’sUniversityHospital,LeedsandProfessor,UniversityofLeeds, Leeds,UK 2Professor,DepartmentofAnaesthesiaandResearch,UniversityofBasel,Switzerland 3Consultant,DepartmentofAnaesthesia

2021 Association of Anaesthetists of GB and Ireland

8. Chemotherapy in Combination with Radiotherapy for Definitive-intent Treatment of Stage II to IVA Nasopharyngeal Carcinoma

and/or with extranodal extension, N2 disease, or primary tumor extension to areas that drain to level 1b as the first echelon site. The safety of lower neck sparing in uninvolved side of the neck was demonstrated in a meta-analysis, a small RCT for N0 patients, and several retrospective studies. - CLINICAL QUESTION 2 What is the recommended chemotherapy sequence in addition to radiotherapy for patients with stage II-IVA nasopharyngeal carcinoma? Recommendation 2.1. For patients with T2N0 (AJCC 8th) NPC, chemotherapy (...) Anthony T. C. Chan ; , MD 11 x Chao-Su Hu ; , MD 12 x Jin-Yi Lang ; , MD 4 x Quynh-Thu Le ; , MD 13 x Anne W. M. Lee ; , MD 14 x Nancy Lee ; , MD 15 x Jin-Ching Lin ; , MD 10 x Brigette Ma ; , MR 16 x Thomas J. Morgan ; , MD 14 x Jatin Shah ; , MD 1 x Ying Sun ; and , MD 1 x Jun Ma 1 Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy

2021 American Society of Clinical Oncology Guidelines

9. Video-Assisted Thoracoscopic Sleeve Lobectomy for Centrally Located Non-small Cell Lung Cancer: A Meta-analysis

Video-Assisted Thoracoscopic Sleeve Lobectomy for Centrally Located Non-small Cell Lung Cancer: A Meta-analysis Video-Assisted Thoracoscopic Sleeve Lobectomy for Centrally Located Non-small Cell Lung Cancer: A Meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get (...) Thoracoscopic Sleeve Lobectomy for Centrally Located Non-small Cell Lung Cancer: A Meta-analysis , , , , Affiliations Expand Affiliations 1 Lung Cancer Center, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041, Sichuan, People's Republic of China. 2 Lung Cancer Center, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041, Sichuan, People's Republic of China. tangxiaojun73@163.com. PMID: 33230587 DOI: Item in Clipboard Review Video-Assisted Thoracoscopic

2021 EvidenceUpdates

10. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER)

A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER) A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get (...) . A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER) , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Radiation Oncology, University of California, Los Angeles, CA, USA. 2 Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA. 3 Department of Medicine, Statistics Core, University of California, Los Angeles, CA, USA. 4 Department of Urology, Mayo Clinic, Rochester, MN, USA

2021 EvidenceUpdates

11. Immunotherapy or other anti-cancer treatments and risk of exacerbation and mortality in cancer patients with COVID-19: a systematic review and meta-analysis Full Text available with Trip Pro

Immunotherapy or other anti-cancer treatments and risk of exacerbation and mortality in cancer patients with COVID-19: a systematic review and meta-analysis Immunotherapy or other anti-cancer treatments and risk of exacerbation and mortality in cancer patients with COVID-19: a systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) Oncoimmunology Actions . 2020 Sep 22;9(1):1824646. doi: 10.1080/2162402X.2020.1824646. Immunotherapy or other anti-cancer treatments and risk of exacerbation and mortality in cancer patients with COVID-19: a systematic review and meta-analysis , Affiliations Expand Affiliations 1 School of Clinical Medicine, Weifang Medical University, Weifang, China. 2 Department of Oncology, Affiliated Hospital of Weifang Medical University, Weifang, China. PMID: 33294299 PMCID: DOI: Free PMC article Item in Clipboard Meta

2021 EvidenceUpdates

12. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial

options Format Erratum in [No authors listed] [No authors listed] Lancet Oncol. 2021 Jan;22(1):e5. doi: 10.1016/S1470-2045(20)30733-6. Lancet Oncol. 2021. PMID: 33387508 No abstract available. Abstract Background: 10-year results from several studies showed improved disease-free survival and distant metastasis-free survival, reduced breast cancer-related mortality, and variable effects on overall survival with the addition of partial or comprehensive regional lymph node irradiation after surgery (...) -III breast adenocarcinoma with involved axillary nodes or a central or medially located primary tumour. Surgery consisted of mastectomy or breast-conserving surgery and axillary staging. Patients were randomly assigned (1:1) centrally using minimisation to receive IM-MS irradiation at 50 Gy in 25 fractions (IM-MS irradiation group) or no IM-MS irradiation (control group). Stratification was done for institution, menopausal status, site of the primary tumour within the breast, type of breast

2021 EvidenceUpdates

13. Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Grade Neuroendocrine Carcinoma of the Lung: JCOG1205/1206

navigation J Clin Oncol Actions . 2020 Dec 20;38(36):4292-4301. doi: 10.1200/JCO.20.01806. Epub 2020 Nov 2. Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Grade Neuroendocrine Carcinoma of the Lung: JCOG1205/1206 , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi-cho Sunto-gun, Japan. 2 Department of Thoracic Oncology, National Cancer Center Hospital (...) Resected High-Grade Neuroendocrine Carcinoma of the Lung: JCOG1205/1206 Hirotsugu Kenmotsu et al. J Clin Oncol . 2020 . Show details Display options Display options Format J Clin Oncol Actions . 2020 Dec 20;38(36):4292-4301. doi: 10.1200/JCO.20.01806. Epub 2020 Nov 2. Authors , , , , , , , , , , , , , , , , , , , Affiliations 1 Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi-cho Sunto-gun, Japan. 2 Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan. 3

2021 EvidenceUpdates

14. Exercise in Cancer Care

• Exercise recommendations to be tailored to the individual’s abilities noting that specific exercise programming adaptations may be required for people with cancer based on disease and treatment-related adverse effects, anticipated disease trajectory and their health status • Effective exercise prescriptions can be delivered across a variety of settings including hospital, cancer treatment centre, community and home-based (i.e. self-managed). • Accredited exercise physiologists or physiotherapists (...) such as cardiovascular disease, diabetes and osteoporosis [3, 4]. Furthermore, epidemiological research suggests that being physically active provides a protective effect against cancer recurrence, cancer-specific mortality and all-cause mortality for some types of cancer (research has predominantly focused on breast, colorectal and prostate cancers) [3, 18-27]. These findings have set the scene for a number of clinical trials, which are currently underway to rigorously evaluate the effects of exercise on cancer

2021 Clinical Oncology Society of Australia

15. Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer Full Text available with Trip Pro

Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) navigation J Clin Oncol Actions . 2020 Dec 20;38(36):4231-4239. doi: 10.1200/JCO.20.01932. Epub 2020 Oct 29. Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. 2 Department of Oncology, Shanghai Medical College

2021 EvidenceUpdates

16. Enhanced neoplasia detection in chronic ulcerative colitis: the ENDCaP-C diagnostic accuracy study Full Text available with Trip Pro

of Inflammatory Bowel Disease, Queen Elizabeth Hospital, Gateshead, UK 3 Institute of Cancer and Genomic Science, University of Birmingham, Birmingham, UK 4 Department of Gastroenterology, Queen Alexandra Hospital Portsmouth, Portsmouth, UK 5 Department of Gastroenterology, New Cross Hospital, Wolverhampton, UK 6 Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK 7 Department of Gastroenterology, Basingstoke and North Hampshire Hospital, Basingstoke, UK 8 West Midlands Regional Genetics (...) Enhanced neoplasia detection in chronic ulcerative colitis: the ENDCaP-C diagnostic accuracy study Enhanced neoplasia detection in chronic ulcerative colitis: the ENDCaP-C diagnostic accuracy study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need

2021 NIHR HTA programme

17. Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer

that were outstanding after the technical engagement stage. The condition The condition There is an unmet need for treatments for BRAF V600E There is an unmet need for treatments for BRAF V600E mutation-positive metastatic colorectal cancer mutation-positive metastatic colorectal cancer 3.1 Colorectal cancer is a malignant tumour arising from the lining of the large intestine (colon and rectum). BRAF is a human gene that encodes the protein B-Raf, which influences cell growth. Metastatic colorectal (...) of Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668) © NICE 2021. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 10 of 30chemotherapy (FOLFIRI or irinotecan) plus cetuximab. It included people with BRAF V600E mutation-positive metastatic colorectal cancer whose disease had progressed after 1 or 2 previous lines of treatment. The primary endpoints in the trial were

2021 National Institute for Health and Clinical Excellence - Technology Appraisals

18. Options for Prevention and Management of Menstrual Bleeding in Adolescent Patients Undergoing Cancer Treatment

for adolescents with thrombocytopenia who are at risk of developing an intramuscular hematoma with intramuscular administration. Progestin-Only Long-Acting Reversible Contraceptive Methods Although there are limited data regarding menstrual management with an LNG-IUD in patients undergoing cancer treatment, it is a reasonable option to manage heavy menstrual bleeding in a patient with benign or malignant disease . Furthermore, the World Health Organization and the Centers for Disease Control and Prevention (...) , initial irregular bleeding with DMPA makes it a less reliable method for rapid therapeutic menstrual suppression, and episodes of breakthrough bleeding can be challenging to manage, particularly in patients who are not candidates for adjuvant estrogen. It is classified as a Category 2 method (the advantages of using the method generally outweigh the theoretical or proven risks) among those with a history of VTE and active cancer according to the Centers for Disease Control and Prevention’s U.S

2021 American College of Obstetricians and Gynecologists

19. Brigatinib (Alunbrig) - for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)

Brigatinib (Alunbrig) - for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) Published 18 January 2021 1 Product update SMC2314 brigatinib 30mg, 90mg and 180mg film-coated tablets (Alunbrig®) Takeda UK Ltd 4 December 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC Executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs (...) ) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated submission brigatinib (Alunbrig®) is accepted for use within NHSScotland. Indication under review: as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor. Brigatinib offers an additional treatment choice in the therapeutic class of tyrosine kinase inhibitors

2021 Scottish Medicines Consortium

20. Talazoparib (Talzenna) - for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer

Talazoparib (Talzenna) - for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer Published 18 January 2021 Statement of advice SMC2325 talazoparib 0.25mg/1mg hard capsules (Talzenna®) Pfizer Ltd 4 December 2020 ADVICE: in the absence of a submission from the holder of the marketing authorisation talazoparib (Talzenna®) is not recommended for use within NHSScotland. Indication under review: As monotherapy (...) for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo) adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy

2021 Scottish Medicines Consortium